OTC:WINT
WINDTREE THERAPEUTICS INC /DE/
A pre-revenue biopharmaceutical developer targeting metabolic diseases with a robust pipeline backed by substantial financing but carrying high operational risk.
Key Metrics
Investment Thesis
Bull Case
Early-stage biotech investors may see value in Wintree's specialized focus on metabolic diseases where the market demand is growing rapidly and competition remains low. The company's ability to secure substantial financing rounds demonstrates investor confidence in its pipeline potential despite current lack of commercial revenue. Successful clinical trials could unlock significant value through licensing deals or partnerships with large pharmaceutical companies.
Bear Case
The absence of any revenue stream combined with massive accumulated losses makes the company highly dependent on continuous successful fundraising, which is increasingly difficult for small-cap biotech firms. Current cash reserves are insufficient to sustain operations without additional capital raises that would likely result in significant shareholder dilution. The high operating expenses and negative cash flow from operations suggest the business model requires substantial time before achieving profitability.
About WINDTREE THERAPEUTICS INC /DE/
Wintree Therapeutics is a biopharmaceutical company focused on developing novel therapies for metabolic diseases and rare genetic disorders, primarily serving markets in the United States and Europe. The company leverages proprietary technologies to create targeted treatments for conditions such as obesity, diabetes, and inflammatory diseases. Its pipeline represents significant potential value despite current lack of commercial revenue.
Analysis
Management Discussion
Management has successfully secured significant capital through financing activities totaling $12.7M, offsetting substantial operating losses of -$15.4M and maintaining a positive cash position despite negative net income. The company continues to invest heavily in research and development at $16.3M while managing administrative costs of $8.7M, though the retained earnings deficit of -$846.6M indicates long-term funding challenges. Recent cash flow from operations turned significantly more negative compared to prior periods, suggesting increased operational intensity or one-time expenses.
Industry Overview
The metabolic disease therapeutics sector is experiencing a boom driven by rising obesity rates and aging populations, creating enormous market opportunities for innovative treatments. Biotechnology companies in this space typically operate with long development cycles requiring substantial capital investment before any commercial returns are realized. Success depends on navigating complex regulatory pathways and achieving positive clinical trial results to gain approval from agencies like the FDA.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $41.3M | $20.6M | $26.1M |
| Operating Income | $-41.3M | $-20.6M | $-26.1M |
| R&D | $11.1M | $8.3M | $16.3M |
| G&A | $10.8M | $9.2M | $8.7M |
| Stock-Based Comp | $3.1M | $1.3M | $455.0K |
| Depreciation | $533.0K | $82.0K | $84.0K |
| Other OpEx | $19.4M | $3.1M | $1.1M |
| Non-Operating Income | $758.0K | $306.0K | $24.3M |
| Interest Expense | $53.0K | $50.0K | — |
| Interest Income | $109.0K | $325.0K | $70.0K |
| Pre-Tax Income | $-40.6M | $-20.3M | $-1.8M |
| Income Tax | $-1.4M | $0 | $-6.0K |
| Continuing Ops | $-39.2M | $-20.3M | $-1.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-39.2M | $-20.3M | $-1.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-39.2M | $-20.3M | $-1.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $7.4M | $5.4M | $2.6M |
| Cash & Equivalents | $6.2M | $4.3M | $1.8M |
| Prepaid Expenses | $1.2M | $1.1M | $795.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $30.6M | $27.0M | $25.3M |
| PP&E (Net) | $262.0K | $183.0K | $111.0K |
| Intangibles | $9.7M | — | — |
| Goodwill | $3.1M | $0 | — |
| Operating Leases | $1.9M | $1.4M | $1.1M |
| Other LT Assets | $15.7M | $25.4M | $24.1M |
| Total Assets | $38.0M | $32.4M | $27.9M |
| Current Liabilities | $2.5M | $4.0M | $5.7M |
| Accounts Payable | $249.0K | $809.0K | $1.9M |
| Current Leases | $404.0K | $436.0K | $508.0K |
| Other Current Liab | $252.0K | $1.1M | $1.6M |
| Long-Term Liabilities | $25.5M | $25.0M | $9.0M |
| LT Operating Leases | $1.6M | $1.2M | $653.0K |
| Other LT Liab | $23.9M | $23.9M | $8.3M |
| Total Liabilities | $27.9M | $29.0M | $14.7M |
| Shareholders' Equity | $10.0M | $3.4M | $13.2M |
| Paid-In Capital | $837.6M | $851.3M | $859.7M |
| Retained Earnings | $-824.5M | $-844.8M | $-846.6M |
| Treasury Stock | $3.1M | — | — |
| Total L&E | $38.0M | $32.4M | $27.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-39.2M | $-20.3M | $-1.8M |
| Non-Cash Adjustments | $23.1M | $6.3M | $-13.3M |
| Working Capital Changes | $-3.4M | $603.0K | $-349.0K |
| Cash from Operations | $-19.5M | $-13.4M | $-15.4M |
| Capital Expenditures | $13.0K | $15.0K | $12.0K |
| Cash from Investing | $197.0K | $-15.0K | $-12.0K |
| Dividends Paid | — | — | $657.0K |
| Cash from Financing | $3.1M | $11.6M | $12.7M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-16.2M | $-1.9M | $-2.7M |
| Beginning Cash | $22.5M | $6.3M | $4.5M |
| Ending Cash | $6.3M | $4.5M | $1.8M |
Frequently Asked Questions
How does WINDTREE THERAPEUTICS INC /DE/ make money?
The company operates primarily through its drug development programs for metabolic disease indications and rare genetic disorders, with no current commercial product sales. Revenue generation is currently funded entirely by cash flow from financing activities and equity issuances rather than product sales. The organization also manages non-core assets including long-term investments and lease obligations separate from its core R&D operations.
What are the main risks for WINT?
Complete reliance on external financing due to zero revenue creates extreme vulnerability to capital market conditions or dilution events. Significant cash burn from R&D operations ($16.3M) and general administration ($8.7M) with minimal cash reserves remaining after recent net change in cash of -$2.7M. High probability of stock price volatility typical for pre-revenue biotech companies without established commercial partnerships.
What is WINT's competitive advantage?
Access to a diverse pipeline of novel compounds targeting unmet needs in the metabolic disease space with potential for high market capture. Strong balance sheet supported by recent equity issuances providing runway for clinical trials and strategic partnerships. Proprietary intellectual property protecting key assets in obesity and diabetes treatments from generic competition.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.